C76/100
Desk Score
Dispatch #9Editorial
Hims & Hers
Mass-market app-first program with nationwide polish — tirzepatide pricing disclosure lags the board.
Visit Hims & Hers ↗Editorial — no commercial relationship.
- Semaglutide
- $199/mo
- Tirzepatide
- Not disclosed
- Coverage
- All 50 states
- Brand-name
- Compounded only
Desk Score breakdown
Each of the six scored dimensions. See the methodology.
Price transparency74/100
State access94/100
Molecule range74/100
Onboarding speed80/100
Support responsiveness74/100
Licensing & trust76/100
What the Desk likes
- All 50 states covered
- Polished consumer app experience
- Strong brand recognition
Where points come off
- Tirzepatide pricing inconsistently disclosed
- Industry-wide compounding scrutiny applies
The Desk's briefing — C
Best for: People who want a familiar consumer-brand app experience and don't need tirzepatide.
Pricing and verification reflect Hims & Hers's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on Hims & Hers's site. Not medical advice; see our disclosure.